JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
批准号:
10770350
负责人:
Opeyemi Ayodeji Olabisi
金额:
$12.5万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-09-20 至 2026-05-31
关键词:
AcuteAffectAfrican ancestryAlbuminuriaApolipoproteinsBiological ProcessBlack AmericanBlood PressureBlood Pressure MonitorsChronicChronic stressCommunitiesCross-Sectional StudiesDevelopmentDiagnosticDisease ProgressionEnrollmentEnvironmental Risk FactorEquipment and supply inventoriesEventFundingFutureGene ExpressionGenesGenotypeGoalsHealthHigh PrevalenceHypertensionImpairmentIndividualInflammationInflammatory ResponseKidneyKidney DiseasesKidney FailureLifeLife Cycle StagesLife StressLogistic RegressionsLogisticsMeasuresMentored Patient-Oriented Research Career Development AwardMentorshipModelingModificationMutationNational Institute on Minority Health and Health DisparitiesOutcomePathogenicityPatientsPhysiologicalPhysiological ProcessesPopulationPositioning AttributeProspective StudiesPsychological StressPsychosocial StressReportingResearchResearch PersonnelRiskStressSympathetic Nervous SystemSystemTestingTherapeuticVariantblack patientblood pressure elevationblood pressure regulationcareer developmentcaucasian Americancohortcommunity partnershipcytokineearly life stressethnic disparityexperiencegene environment interactionhigh riskhuman modelinflammatory markerinsightinstrumentinterestkidney dysfunctionmouse modelnovel strategiesnovel therapeuticspatient engagementpreventracial disparityrisk variantstress reductionstressor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Black Americans are disproportionately affected by kidney disease progression compared to White Americans.
Mutations in the Apolipoprotein L1 (APOL1) gene have been implicated in this racial/ethnic disparity in kidney
health. However, not all individuals who carry high risk APOL1 variants develop kidney failure. Psychosocial
stress, commonly reported among Black Americans, may serve as a potential exacerbating factor which may
increase the risk of kidney disease through inflammation and stimulation of the sympathetic nervous system.
The central hypothesis of this proposal is that cumulative life stress is associated with the dysregulation of
multiple physiological systems, favoring the development of APOL1 associated kidney disease.
In a prospective study, this proposal will investigate the association between cumulative life stress and
dysregulation of physiologic processes among Southern-dwelling Black patients. Aim1A will evaluate whether
Southern-dwelling patients of African ancestry with high levels of cumulative life stress will experience higher
levels of inflammatory markers and blood pressure compared to patients with low cumulative life stress; Aim1B
will evaluate whether an interaction between Southern-dwelling patients of African ancestry with high
cumulative life stress and a high risk APOL1 genotype is associated with higher levels of inflammatory markers
and elevated blood pressure. Aim 2A will evaluate whether Southern-dwelling patients of African ancestry with
high levels of stress will have a higher prevalence of kidney dysfunction, manifested by albuminuria ≥20mg/g
and reduced eGFR <75ml/min/1.73m2, compared to those with low levels of cumulative life stress; Aim 2B will
evaluate whether an interaction between Southern-dwelling patients of African ancestry with high cumulative
life stress and high risk APOL1 genotype is associated with kidney dysfunction among Southern-dwelling
patients of African ancestry. Leveraging the Community APOL1 research Engagement cohort, we will
accomplish these proposed aims by enrolling 400 Southern-dwelling Black patients and conducting a cross-
sectional analysis of the relationship between cumulative life stress and inflammation, elevated blood pressure,
and kidney dysfunction. We will also evaluate how APOL1 high risk variant modifies the aforementioned
relationships between cumulative life stress and our outcomes of interest.
Execution of these scientific aims and career development activities outlined in this proposal, and a strong
mentorship team, will position Dr. Lucas to establish herself as a successful junior investigator on a future
mentored patient-oriented research career development award (K23) focused on psychosocial stress and
kidney disease among Black Americans.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
APOL1 channel blocker reduces proteinuria in FSGS.
APOL1 通道阻滞剂可减少 FSGS 中的蛋白尿。
DOI:
10.1016/j.kint.2023.04.022
发表时间:
2023
期刊:
Kidney international
影响因子:
19.6
作者:
[Olabisi,OpeyemiA]
通讯作者:
Olabisi,OpeyemiA
DOI:
10.1016/j.kint.2021.04.023
发表时间:
2021-07
期刊:
KIDNEY INTERNATIONAL
影响因子:
19.6
作者:
[Olabisi, Opeyemi A., Freedman, Barry I.]
通讯作者:
Freedman, Barry I.
DOI:
10.1016/j.ekir.2021.06.005
发表时间:
2021-09
期刊:
Kidney international reports
影响因子:
6
作者:
[DeOliveira M, Feeney C, Leahy C, Nystrom S, Howell DN, Farouk SS, Wu M, Olabisi OA, Sparks MA]
通讯作者:
Sparks MA
JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
-
批准号:10491289
-
项目类别:
-
资助金额:$67.19万
-
财政年份:2021
-
负责人:Opeyemi Ayodeji Olabisi
-
依托单位:
JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
-
批准号:10625485
-
项目类别:
-
资助金额:$65.99万
-
财政年份:2021
-
负责人:Opeyemi Ayodeji Olabisi
-
依托单位:
JAK-STAT Inhibition to Reduce Racial Disparities in Kidney Disease
-
批准号:10277536
-
项目类别:
-
资助金额:$67.62万
-
财政年份:2021
-
负责人:Opeyemi Ayodeji Olabisi
-
依托单位:
海外基金